Promising new cocktail aims to tame multiple myeloma with fewer side effects
NCT ID NCT02412228
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of three drugs—ixazomib, cyclophosphamide, and dexamethasone—as a first treatment for multiple myeloma. The goal was to see if this mix works better and causes fewer nerve problems than standard options. Twelve newly diagnosed patients took part, receiving the drugs in cycles over about 1.5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ixazomib (a targeted cancer drug), cyclophosphamide (a chemotherapy drug), and dexamethasone (a steroid)
What this could lead to
If successful, this combination could offer a more effective and less toxic first-line treatment option for multiple myeloma, potentially improving outcomes and quality of life.
What could go wrong
This is a small, early-phase trial with only 12 participants, so results may not apply broadly. The drugs still carry risks of side effects, and the regimen may not prove superior to existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Hospital of Rhode Island
Pawtucket, Rhode Island, 02860, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
The Miriam Hospital
Providence, Rhode Island, 02906, United States